ADC.AU ACDC Metals Ltd
Market Closed 04-04 16:12:00 AEDT
0.05
+0.00
0.00%
High
0.05
Low
0.05
Vol
0.00
Open
0.05
D1 Closing
0.05
Amplitude
0.00%
Mkt Cap
3.30M
Tradable Cap
1.77M
Total Shares
73.28M
T/O
0.00
T/O Rate
0.00%
Tradable Shares
39.34M
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
Loading ...
News
New Post(s)
Profile
Dominari Holdings reports preliminary 2024 revenue of $19M, up 900%
Grafa · 03-28
Dominari Holdings reports preliminary 2024 revenue of $19M, up 900%
Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation
MT Newswires Live · 03-27
Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation
Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech
MT Newswires Live · 03-18
Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech
CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug
MT Newswires Live · 03-06
CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug
ArriVent hits trial milestone, closes 2024 with $266.5M cash
Grafa · 03-03
ArriVent hits trial milestone, closes 2024 with $266.5M cash
Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%
MT Newswires Live · 03-03
Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%
Coles share price lifts off on dividend boost
MotleyFool · 02-26
Coles share price lifts off on dividend boost
AstraZeneca's Datroway get FDA nod for breast cancer treatement
Grafa · 01-21
AstraZeneca's Datroway get FDA nod for breast cancer treatement
Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug
MT Newswires Live · 01-21
Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug
Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility
MT Newswires Live · 01-17
Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility
Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences
MT Newswires Live · 01-10
Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences
FDA grants breakthrough therapy designation to GSK's osteosarcoma drug
Grafa · 01-07
FDA grants breakthrough therapy designation to GSK's osteosarcoma drug
Agree Realty Expects to Invest Up to $1.3 Billion in 2025
MT Newswires Live · 01-06
Agree Realty Expects to Invest Up to $1.3 Billion in 2025
Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3
MT Newswires Live · 01-02
Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3
IDEAYA inks $1.045B licensing deal with Hengrui for cancer therapy
Grafa · 2024-12-30
IDEAYA inks $1.045B licensing deal with Hengrui for cancer therapy
Aadi Bioscience shares jump on licensing agreement for cancer drugs
Grafa · 2024-12-20
Aadi Bioscience shares jump on licensing agreement for cancer drugs
Is the Coles share price a buy amid its 2025 outlook?
MotleyFool · 2024-12-12
Is the Coles share price a buy amid its 2025 outlook?
Trump Media saw the largest increase in short interest in October
seekingalpha · 2024-11-20
Trump Media saw the largest increase in short interest in October
BRIEF-Coles Update On Supply Chain Modernisation
Reuters · 2024-10-31
BRIEF-Coles Update On Supply Chain Modernisation
Coles share price climbs on Q1 update and $880m investment news
MotleyFool · 2024-10-30
Coles share price climbs on Q1 update and $880m investment news
Load more
Introduction
Company Name.
ACDC Metals Ltd
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App
{"stockData":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.045,"timestamp":1743743520000,"preClose":0.045,"halted":0,"volume":0,"delay":0,"nameEN":"ACDC Metals Ltd","floatShares":39337511,"shares":73275130,"eps":-0.005605,"marketStatus":"Market Closed","change":0,"latestTime":"04-04 16:12:00 AEDT","open":0.045,"high":0.045,"low":0.045,"amount":0,"amplitude":0,"askPrice":0.05,"askSize":192538,"bidPrice":0.045,"bidSize":14222,"shortable":3,"etf":0,"ttmEps":-0.005605,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1743984000000},"marketStatusCode":7,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.045,"openAndCloseTimeList":[[1743721200000,1743742800000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/ADC.AU","defaultTab":"news","newsList":[{"id":"2522571518","title":"Dominari Holdings reports preliminary 2024 revenue of $19M, up 900%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522571518","media":"Grafa","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522571518?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:49","pubTimestamp":1743166187,"startTime":"0","endTime":"0","summary":"Dominari Holdings , a financial services and investment firm, today announced its preliminary, unaudited revenue results for the full year ended December 31, 2024, showcasing remarkable growth.The company anticipates total revenue of approximately $19 million for 2024, a staggering 900% increase from $2 million in 2023.A robust fourth quarter, contributing over $8 million to the annual total, underscored this performance.Dominari attributes the surge to its successful growth strategy and rising demand for its investment banking services.Key business developments in 2024 further highlight Dominari’s momentum.The company co-founded American Data Centers , securing a 32% ownership stake alongside Donald J. Trump Jr., Eric Trump, and AI industry experts.Additionally, Dominari Securities, a subsidiary, gained FINRA approval to expand operations by adding 50 new seats and opening new office locations.In a forward-looking move, Dominari launched a Bitcoin treasury strategy, investing a portio","market":null,"thumbnail":"https://images.grafa.com/grafa/media-fintech-dominari-holdings-reports-preliminary-2024-revenue-of--19m--up-900--409069-638787630217528063.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-fintech-dominari-holdings-reports-preliminary-2024-revenue-of--19m--up-900--409069-638787630217528063.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/fintech-dominari-holdings-reports-preliminary-2024-revenue-of--19m--up-900--409069?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTC.USD.HKCC","BTC.USD.CC","BK7095","ADC.AU"],"gpt_icon":0},{"id":"2522134338","title":"Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522134338","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522134338?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 15:44","pubTimestamp":1743061459,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology said its novel CD228-directed antibody-drug conjugate , BA1302, received Orphan Drug Designation from the Food and Drug Administration for the treatment of squamous non-small cell lung cancer and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.The biopharmaceutical company's shares were up 2% in recent trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","BK7095","BK4080","BK1161","BK4183","ODD","ADC","06955","ADC.AU"],"gpt_icon":0},{"id":"2520635265","title":"Otsuka's Taiho to Buy Swiss ADC Developer Araris Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2520635265","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520635265?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 08:06","pubTimestamp":1742256371,"startTime":"0","endTime":"0","summary":"Otsuka Holdings said its unit, Taiho Pharmaceutical, will acquire Swiss biotech firm Araris Biotech for up to $1.14 billion to strengthen its antibody-drug conjugate pipeline, according to a Monday filing on the Tokyo Stock Exchange.Taiho will pay $400 million upfront and potential additional milestone payments of up to $740 million. The deal is expected to close in the first half of 2025.Price : $7712.00, Change: $+94, Percent Change: +1.23%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC.AU","BK4231","BK7095","BK4080","ADC"],"gpt_icon":0},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals submitted the Phase I-B trial application in Australia for its large B-cell lymphoma drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate that works with first-line standard-of-care to diffuse large B-cell lymphoma , the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK4080","BK4231","BK1161","XKO.AU","BK7095","XAO.AU","BK1574","ADC","ADC.AU","XJO.AU"],"gpt_icon":0},{"id":"2516633415","title":"ArriVent hits trial milestone, closes 2024 with $266.5M cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633415","media":"Grafa","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633415?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:37","pubTimestamp":1741005441,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma , a clinical-stage biopharmaceutical company, today released its financial results for the 2024 fiscal year, highlighting significant progress in its drug development pipeline and a solid cash position to support future operations.The company achieved a key milestone by meeting its enrollment target for the pivotal Phase 3 trial of firmonertinib, a promising treatment for non-small cell lung cancer patients.This accomplishment marks a critical step forward in ArriVent’s mission to address unmet needs in oncology.Financially, ArriVent reported research and development (R&D) expenses of $79 million for the year ended December 31, 2024, up from $64.9 million in 2023.General and administrative (G&A) expenses also rose to $15.3 million in 2024, compared to $9.7 million in 2023.During the period under review, ArriVent posted a net loss of $80.5 million for 2024, compared to $69.3 million in the prior year, reflecting the increased investment in its clinical programs and o","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-arrivent-hits-trial-milestone--closes-2024-with--266-5m-cash-388724-638766022413665248.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-arrivent-hits-trial-milestone--closes-2024-with--266-5m-cash-388724-638766022413665248.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-arrivent-hits-trial-milestone--closes-2024-with--266-5m-cash-388724?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","IND.AU","BK7095"],"gpt_icon":0},{"id":"2516576704","title":"Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516576704","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516576704?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 12:21","pubTimestamp":1740975711,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical said the first patient was enrolled in its phase three trial for BL-B01D1, according to a Monday filing with the Shanghai bourse.BL-B01D1 is a dual antibody-drug conjugate combined with Osimertinib for treating EGFR-mutated advanced non-small cell lung cancer.Shares of the pharmaceutical company were down 4% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","BK4080","ADC.AU","688506","BK4231","BK0239","BK7095"],"gpt_icon":0},{"id":"2514789050","title":"Coles share price lifts off on dividend boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2514789050","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514789050?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 07:33","pubTimestamp":1740612790,"startTime":"0","endTime":"0","summary":"Commenting on the results boosting the Coles share price today, CEO Leah Weckert said: We have had a strong focus on value, fresh quality and availability which has supported volume-led growth in Supermarkets during the half…Looking at what could impact the Coles share price in the months ahead, the company reported that in the first seven weeks of the third quarter , its Supermarkets sales revenue grew by 3.4% compared to the same period last year. Coles Liquor segment posted sales revenue growth of 3.8%. \"Our focus in the second half remains on providing a compelling customer value proposition, making further progress on improving our fresh offer and continuing to tailor our ranges to make","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/27/coles-share-price-lifts-off-on-dividend-boost/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7095","ADC","XJO.AU","COL.AU","BK7040","BK4080","ADC.AU","BK7082","BK7501","BK4231"],"gpt_icon":0},{"id":"2505700226","title":"AstraZeneca's Datroway get FDA nod for breast cancer treatement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505700226","media":"Grafa","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505700226?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 19:51","pubTimestamp":1737460306,"startTime":"0","endTime":"0","summary":"AstraZeneca has announced that its new drug Datroway, also known as datopotamab deruxtecan, has been approved by the U.S. FDA to treat adults with unresectable or metastatic HR-positive, HER2-negative breast cancer.The approval is based on positive results from the TROPION-Breast01 Phase III trial, which demonstrated a significant 37% reduction in the risk of disease progression or death in patients treated with Datroway compared to those receiving chemotherapy.\"The approval of datopotamab deruxtecan, a novel TROP2-directed antibody drug conjugate, marks a major therapeutic milestone and provides patients with metastatic breast cancer a new treatment alternative to conventional chemotherapy,\" said Aditya Bardia, MD, MPH, the global principal investigator for the trial.The trial's safety analysis showed that Datroway's safety profile was consistent with previous findings, with no new safety concerns identified.Meanwhile, Datroway is a specifically engineered TROP2-directed antibody-dru","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-astrazeneca-s-datroway-get-fda-nod-for-breast-cancer-treatement-353180-638730571065178831.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-astrazeneca-s-datroway-get-fda-nod-for-breast-cancer-treatement-353180-638730571065178831.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-astrazeneca-s-datroway-get-fda-nod-for-breast-cancer-treatement-353180?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK7095"],"gpt_icon":0},{"id":"2505627362","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod for Solid Tumors Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505627362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505627362?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 10:39","pubTimestamp":1737427147,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.SKB445, a new antibody-drug conjugate drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.The pharmaceutical company's shares were up by 1% in recent trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC.AU","BK4080","06990","BK7095","BK4231","BK1161","ADC","LU0196878994.USD"],"gpt_icon":0},{"id":"2504972351","title":"Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2504972351","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504972351?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 10:18","pubTimestamp":1737080302,"startTime":"0","endTime":"0","summary":"Samsung Biologics entered the antibody-drug conjugate sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.The company has deepened its collaboration with LigaChem Biosciences , signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","BK4080","BK4231","BK7095","ADC.AU"],"gpt_icon":0},{"id":"2502072716","title":"Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2502072716","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502072716?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 08:57","pubTimestamp":1736470660,"startTime":"0","endTime":"0","summary":"Samsung Biologics extended its partnership with LigaChem Biosciences to provide antibody-drug conjugate services at its new ADC facility, the South Korean biotechnology firm said Thursday.The collaboration focuses on ADC programs for solid tumor treatments. Samsung's facility, equipped with a 500-liter reactor, offers end-to-end ADC services from development to conjugation, using its expertise in large-scale antibody manufacturing, it said.Shares of Samsung Biologics rose nearly 1% in recent trade on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC.AU","BK7095","BK4231","BK4080","ADC"],"gpt_icon":0},{"id":"2501270327","title":"FDA grants breakthrough therapy designation to GSK's osteosarcoma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2501270327","media":"Grafa","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501270327?lang=en_us&edition=full_marsco","pubTime":"2025-01-07 19:52","pubTimestamp":1736250760,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to GSK5764227 , an antibody-drug conjugate being developed by GSK , for the treatment of relapsed or refractory osteosarcoma in adults.This form of bone cancer presents a significant challenge, with no currently approved FDA treatments for patients who have progressed after two prior lines of therapy.GSK'227 targets B7-H3 and is being investigated in the ARTEMIS-002 phase II trial.This study has assessed the drug's efficacy and safety in over 60 patients, including 42 with osteosarcoma, generating promising data that led to the FDA's designation.\"This latest regulatory designation for GSK'227 exemplifies the potential of our targeted ADC in patients with difficult-to-treat cancers,\" said Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK.The Breakthrough Therapy Designation is designed to expedite the development and review of drugs intended to treat serious conditions and demonstra","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-fda-grants-breakthrough-therapy-designation-to-gsk-s-osteosarcoma-drug-344695-638718475602966087.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-fda-grants-breakthrough-therapy-designation-to-gsk-s-osteosarcoma-drug-344695-638718475602966087.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-fda-grants-breakthrough-therapy-designation-to-gsk-s-osteosarcoma-drug-344695?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","ADC.AU"],"gpt_icon":0},{"id":"2501601762","title":"Agree Realty Expects to Invest Up to $1.3 Billion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501601762","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501601762?lang=en_us&edition=full_marsco","pubTime":"2025-01-07 05:32","pubTimestamp":1736199169,"startTime":"0","endTime":"0","summary":"Agree Realty said Monday it expects to invest $1.1 billion to $1.3 billion in 2025.The investments will include capital deployment through the acquisition, development and developer funding platform, the company said.Total real estate investment volume in 2024 was $951 million, the company said.Share of Agree Realty fell 1.8% in recent after-hours activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADC","BK7095","BK4080","ADC.AU","BK4231"],"gpt_icon":0},{"id":"2500999346","title":"Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3","url":"https://stock-news.laohu8.com/highlight/detail?id=2500999346","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500999346?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 13:10","pubTimestamp":1735794641,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.This collaboration aims to bring ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4231","01801","BK7095","LU2328871848.SGD","ADC","LU2488822045.USD","BK1161","ADC.AU","BK4080","LU1969619763.USD","BK1583","BK1589"],"gpt_icon":0},{"id":"2495548676","title":"IDEAYA inks $1.045B licensing deal with Hengrui for cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2495548676","media":"Grafa","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495548676?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 19:35","pubTimestamp":1735558551,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences has announced a major licensing agreement with Jiangsu Hengrui Pharmaceuticals for SHR-4849, a novel antibody drug conjugate targeting DLL3, a protein highly expressed in small cell lung cancer and neuroendocrine tumors .The deal grants IDEAYA exclusive global rights to develop and commercialize SHR-4849 outside of Greater China.SHR-4849 utilizes a Topoisomerase I inhibitor payload to target and destroy cancer cells expressing DLL3.This targeted approach offers potential for improved efficacy and reduced side effects compared to traditional chemotherapy.The agreement includes significant financial incentives for Hengrui Pharma.They are eligible to receive up to $1.045 billion in total payments, including a $75 million upfront payment, up to $200 million in development and regulatory milestone payments, and additional commercial milestones based on sales performance.Hengrui will also receive royalties ranging from mid-single to low-double digits on net sales outsi","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-ideaya-inks--1-045b-licensing-deal-with-hengrui-for-cancer-therapy-340654-638711553511464280.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-ideaya-inks--1-045b-licensing-deal-with-hengrui-for-cancer-therapy-340654-638711553511464280.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-ideaya-inks--1-045b-licensing-deal-with-hengrui-for-cancer-therapy-340654?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK7095","IND.AU"],"gpt_icon":0},{"id":"2492577417","title":"Aadi Bioscience shares jump on licensing agreement for cancer drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492577417","media":"Grafa","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492577417?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 20:25","pubTimestamp":1734697555,"startTime":"0","endTime":"0","summary":"Shares of Aadi Bioscience surged nearly 40% in premarket trading today, reaching $3.25, after the company announced a major collaboration with Chinese biotechnology leaders and the sale of its existing cancer treatment.Aadi Bioscience entered into an agreement with WuXi Biologics and HANGZHOU DAC, both based in China, to develop and potentially commercialize three promising antibody-drug conjugate therapies.ADCs are a type of targeted cancer treatment that combines an antibody with a cell-killing drug.Under the terms of the agreement, Aadi will pay an upfront sum of $44 million to the Chinese firms, with an additional $805 million in potential milestone payments tied to the development and commercialization of the ADC therapies.Separately, Aadi announced the sale of its FDA-approved cancer treatment, Fyarro, to KAKEN Pharmaceutical for $100 million.The company also expects to raise an additional $100 million through a private investment in public equity financing.Combined with the p","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-aadi-bioscience-shares-jump-on-licensing-agreement-for-cancer-drugs-336766-638702943812304404.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-aadi-bioscience-shares-jump-on-licensing-agreement-for-cancer-drugs-336766-638702943812304404.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-aadi-bioscience-shares-jump-on-licensing-agreement-for-cancer-drugs-336766?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","ADC.AU"],"gpt_icon":0},{"id":"2491368303","title":"Is the Coles share price a buy amid its 2025 outlook?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491368303","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491368303?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 06:11","pubTimestamp":1734041485,"startTime":"0","endTime":"0","summary":"The Coles Group Ltd share price has gone through plenty of volatility this year, but it seems to be ending the year on a high, as shown on the chart below. With the company close to its 52-week high, we're going to look at whether the company is an attractive investment with 2025 in mind. As one of the largest supermarket businesses in Australia, it's benefited from the inflationary period over the last couple of years. However, now that food inflation has significantly reduced, the sector is no longer getting an extra revenue boost. So, will Coles be able to keep growing?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/13/is-the-coles-share-price-a-buy-amid-its-2025-outlook/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7082","BK7040","BK4080","BK7501","EBIT","COL.AU","ADC.AU","BK7511","ADC","BK4231","WOW.AU","BK7095"],"gpt_icon":0},{"id":"2485114959","title":"Trump Media saw the largest increase in short interest in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2485114959","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485114959?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 23:57","pubTimestamp":1732118245,"startTime":"0","endTime":"0","summary":"hyejin kang/iStock via Getty Images Trump Media & Technology (DJT) and Lucid Group (LCID) saw the largest increases in short interest in October, while Expand Energy Corp. (EXE), and Pilgrim’s Pride (","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141852985/image_1141852985.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312369-trump-media-saw-the-largest-increase-in-short-interest-in-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["MC","OLLI","MDGL","NTRA","AAL","CART","ODFL","SFM","HUM.AU","CELH","CRC","EAT","PPC.AU","SFM.AU","XLU","ENPH","CNX","AMTM","DJT","AAL.AU","GAP","LINE","WHR","ENSG","EXE","IWV","DOCU","HUM","FOUR","VRNS","XLP","ADC.AU","VERX","SIRI","CG","GAP.AU","SMMT","RBC","AMKR","SWKS","ADC","CORT","WEX","BIRK","PPC","LCID","APO"],"gpt_icon":1},{"id":"2479304790","title":"BRIEF-Coles Update On Supply Chain Modernisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2479304790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479304790?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 09:10","pubTimestamp":1730337023,"startTime":"0","endTime":"0","summary":"Oct 31 - Coles Group Ltd : * UPDATE ON COLES SUPPLY CHAIN MODERNISATION * INVESTING A$880 MILLION TO DEVELOP A NEW AMBIENT AUTOMATED DISTRIBUTION CENTRE IN TRUGANINA * INVESTING A$880 MILLION TO DEVELOP A NEW AMBIENT AUTOMATED DISTRIBUTION CENTRE * EXPECTS TO RECOGNISE A PROVISION OF AROUND A$35 MILLION BEFORE TAX IN 1H25 * INVESTMENT IN PARTNERSHIP WITH WITRON AUSTRALIAFurther company coverage: ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC.AU","BK7040","BK7501","BK7095","COL.AU","BK7082"],"gpt_icon":0},{"id":"2479931057","title":"Coles share price climbs on Q1 update and $880m investment news","url":"https://stock-news.laohu8.com/highlight/detail?id=2479931057","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479931057?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 07:13","pubTimestamp":1730330006,"startTime":"0","endTime":"0","summary":"The Coles Group Ltd share price is back on form on Thursday. In morning trade, the supermarket giant's shares are up 1% to $17.90. Why is the Coles share price rising?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/31/coles-share-price-climbs-on-q1-update-and-880m-investment-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4231","BK7082","BK7501","BK4080","ADC.AU","COL.AU","ADC","BK7095","BK7040"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.1818},{"period":"6month","weight":-0.1667},{"period":"1year","weight":-0.3077},{"period":"ytd","weight":-0.1818}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0037},{"period":"3month","weight":0.0964},{"period":"6month","weight":0.1319},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1011}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"exchange":"ASX","name":"ACDC Metals Ltd","nameEN":"ACDC Metals Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACDC Metals Ltd(ADC.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACDC Metals Ltd(ADC.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACDC Metals Ltd,ADC.AU,ACDC Metals Ltd股票,ACDC Metals Ltd股票老虎,ACDC Metals Ltd股票老虎国际,ACDC Metals Ltd行情,ACDC Metals Ltd股票行情,ACDC Metals Ltd股价,ACDC Metals Ltd股市,ACDC Metals Ltd股票价格,ACDC Metals Ltd股票交易,ACDC Metals Ltd股票购买,ACDC Metals Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACDC Metals Ltd(ADC.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACDC Metals Ltd(ADC.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}